Newron Pharmaceuticals - Schizophrenia development adds value
Newron is focused on the development of its novel schizophrenia drug, Evenamide. Evenamide is in a 120-patient Phase II study, due to report in Q121. Newron notes that two pivotal Phase III trials could start in Q221. It is progressing possible partnering deals. It also has a marketed product for Parkinson’s disease, Xadago, sold via Zambon in Europe and by Supernus in the US. Xadago H120 royalties were up 14% at €2.5m. Discussions with Zambon to expand the Xadago indication by co-funding a study in Parkinson’s dyskinesia are in progress. Newron has cash and loan facilities to fund it into 2022. Our indicative value is CHF121m.Newron Pharmaceuticals is a clinical stage biopharmaceutical company. Co. is focused on the development of drugs for the treatment of central nervous system disorders and pain. Co.'s pipeline include, Xadago® (safinamide), for the treatment of Parkinson's disease (PD) and PD Levodopa-induced dyskinesia; Sarizotan, for the treatment of Rett syndrome (Orphan drug status); Evenamide (NW-3509), for the treatment of Schizophrenia and Clozapine-treatment-resistant schizophrenia; and Ralfinamide for patients with specific rare pain indications (neuropathic pain).
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.